The Federal Reserve's fight against inflation may soon yield financial benefits.As shown by the industry-tracking SPDR S&P Biotech ETF's (XBI 0.07%) decline of 22% over the last three years, biotech stocks haven't performed well as a group in recent history. But this doesn't mean biotechs have been struggling to get their programs out of the clinic and onto the market any more than usual.There's a different phenomenon at play here. And if macroeconomic forecasts are to be believed, conditions could soon imp ...